Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.

ME, Goebeler; S, Knop; A, Viardot; P, Kufer; MS, Topp; H, Einsele; R, Noppeney; G, Hess; S, Kallert; A, Mackensen; K, Rupertus; L, Kanz; M, Libicher; D, Nagorsen; G, Zugmaier; M, Klinger; A, Wolf; B, Dorsch; BD, Quednau; M, Schmidt; J, Scheele; PA, Baeuerle; E, Leo; RC, Bargou

doi:10.1200/jco.2014.59.1586

Public

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.

Shared by NobleBlocks on Feb 16, 2016 • 12:00 AM UTC

Authors:

Goebeler ME

Knop S

Viardot A

Abstract

Purpose Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the treatment of Philadelphia chromosome-negative acute B-lymphoblastic leukemia. We evaluated blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).Patients and methods This 3 + 3 design, phas...

Discussions